A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic HER2-Expressing Cancers
VIR-5818-V101
Phase 1 other active
Quick answer
A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic HER2-Expressing Cancers for Participants with Locally Advanced or Metastatic HER2-Expressing Cancers is a Phase 1 program (other) at Vir Biotechnology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vir Biotechnology
- Indication
- Participants with Locally Advanced or Metastatic HER2-Expressing Cancers
- Phase
- Phase 1
- Modality
- other
- Status
- active